While innovation from China is increasingly integrated into Western pharma pipelines, there's little expectation of outright acquisitions of Chinese companies. The consensus is that licensing a specific asset is far simpler and avoids the significant political and regulatory complexities of a full M&A transaction.

Regeneron maintains a competitive edge by owning its antibody discovery platform (mice with humanized immune systems). This vertical integration provides full control and consistently yields best-in-class molecules, a feat competitors struggle to replicate even with access to similar third-party services.

Synthakyne operates as a specialized 'cytokine engineering shop.' It develops its own assets in high-value areas like oncology (IL-2, IL-12) while simultaneously licensing its platform for other indications, such as inflammation, through major partnerships with Merck and Sanofi. This strategy generates capital and validates the core technology.

Apogee built its strategy around known biological mechanisms, focusing innovation solely on antibody engineering. This allowed them to de-risk assets early and efficiently (e.g., proving half-life in healthy volunteers). This clear, stepwise reduction of risk proved highly attractive to capital markets, enabling them to raise significant funds for late-stage development.

Paragon Therapeutics operates a venture creation factory. Instead of discovering new targets, it applies its core half-life extension technology to validated biologics to create improved "bio-better" versions. It then spins these assets out into disease-focused companies like Spire (IBD), de-risking development by focusing on engineering and execution rather than novel biology.

Biotech companies create more value by focusing on de-risking molecules for clinical success, not engineering them from scratch. Specialized platforms can create molecules faster and more reliably, allowing developers to focus their core competency on advancing de-risked assets through the pipeline.

For a biotech with an established commercial infrastructure, the most efficient growth strategy is to in-license late-stage or already-approved products. This leverages the existing sales force and operational teams to sell new products without adding significant overhead, maximizing operational efficiency and revenue.

Ipsen avoids the high-risk, capital-intensive phase of basic research. Instead, its R&D strategy focuses on licensing promising drug candidates from universities and biotechs. The company then leverages its expertise in later-stage development, including toxicology, manufacturing scale-up (CMC), and clinical trials, to bring these de-risked assets to market.

Lacking internal research capabilities, Mirum's core business model is to in-license or acquire promising assets. This strategy, initiated in 2018 with assets from Shire, relies on their proven operational team to develop and maximize the value of external innovations.